Product logins

Find logins to all Clarivate products below.


In 2013, Brazil’s total pharmaceutical market for type 2 diabetes rivaled the size of some of the major markets. Increasing public awareness, an aging population, and the launch of new premium-priced antidiabetic agents will all contribute to the growth of this market in the next five years. The large, growing prevalent population promises a 7% annual growth in sales and significant opportunity for multinational pharmaceutical companies as demand for branded antidiabetic drugs continues to grow throughout Brazil.

Related Market Assessment Reports

Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 receptor agonist products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…
Report
Type 1 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment options for type 1 diabetes (T1D) patients are limited; insulins, pramlintide (in the United States), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors (only in Japan) are the…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Type 2 Diabetes – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Metformin remains the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. More effective, safer, and…
Report
Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The type 2 diabetes (T2D) therapy market will expand through 2033, supported by polypharmacy and growing use of later-line therapies offering nonglycemic benefits. However, the loss of exclusivity…